An initial exploration of hair cortisol responses to antidepressants in unmedicated patients with depression

Xiuli Song1,2,*, Wei Cui3,*, Zugui Peng1, Liansheng Zhao1, Xuezhu Yu3, Tao Li1, Lijun Cui3,∗ and Xiaohong Ma1,∗1

Abstract
Objective: Major depressive disorder is associated with abnormal functioning of the hypothalamic–pituitary–adrenal (HPA) axis. Studies using hair cortisol to measure the effect of antidepressants on the HPA axis are lacking. The aim of this study was to explore the long-term effects of antidepressants on hair cortisol concentration (HCC).

Methods: Participants were 42 patients and 36 healthy individuals. The patients took antidepressants for 4 weeks. Patient HCC was measured pre-treatment and post-treatment. The HCC of healthy controls was also measured.

Results: Patient post-treatment HCC (mean ± standard deviation: 34.40 ± 32.57 pmol/mg) was significantly higher than patient pre-treatment HCC (17.42 ± 12.40 pmol/mg) and healthy control HCC (10.22 ± 7.99 pmol/mg). No significant correlation was found between Hamilton Depression Rating Scale scores and HCC at pre-treatment or post-treatment.

Conclusions: Hair cortisol concentration analysis could be used to monitor the dynamics of the effects of antidepressants on the HPA axis.

Keywords
Depression, hair cortisol, antidepressant, biomarker, hypothalamic–pituitary–adrenal axis, Hamilton Depression Rating Scale, China

Date received: 17 May 2019; accepted: 30 October 2019

*These authors contributed equally to this work.

Corresponding author:
Xiaohong Ma, Psychiatric Laboratory and Department of Psychiatry, 1 Ke Yuan 4th Road, West China Hospital, Sichuan University, Chengdu 610041, P. R. China.
Email: maxiaohong@scu.edu.cn
Introduction

Major depressive disorder (MDD) is a serious mental health problem characterized by emotional distress, hopelessness and low activity, which greatly reduce quality of life. MDD may cause serious economic and health problems and even increase the risk of suicide.

The activity of the hypothalamic–pituitary–adrenal (HPA) axis is a key pathophysiological correlate of depression; patients with depression show excessive cortisol, a measure of HPA axis activity. Traditionally, cortisol concentrations have been measured in serum, saliva and urine, and show elevated levels in depressed patients. After antidepressant treatment, HPA axis function is normal and plasma cortisol levels decrease. However, serum, salivary and urinary measures of long-term cortisol levels can be unreliable owing to circadian rhythm variation, sample collection at different time points, food intake and exercise habits.

More recently, hair has been used to measure long-term cortisol levels; this measure can establish the average cortisol secretion level between 1 month and 12 months. In addition, hair cortisol concentration (HCC) is not affected by confounding factors, such as age, tobacco use, hair curvature, washed and unwashed hair, and frequency of hair washing. A previous study comparing cortisol levels in hair to levels obtained with other measures suggests that HCC is very sensitive to HPA axis activity.

Previous studies of patients with depression have shown that serum cortisol levels are substantially reduced after antidepressant treatment. Dettenborn et al. point out the lack of studies using hair cortisol to measure the effects of antidepressants on the HPA axis. The aim of this study was to compare HCC in male and female patients with depression to HCC in healthy controls, and to explore the long-term effects of antidepressants on HCC.

Methods

Participants

Forty-two patients (aged 18–55 years) were recruited from the Mental Health Center of West China Hospital of Sichuan University and from the Mental Health Center of Hebei Province between February 2013 and February 2014. All patients were assessed by trained psychiatrists using the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). The inclusion criteria were (1) duration of depression 1 to 2 months, including first-episodic and recurrent (defined as having depression again after being cured) depression and (2) antidepressant-naive or antidepressant-free for at least 6 months. The exclusion criteria were (1) obvious psychosocial reasons for depression, such as marriage failure, relationship problems, job failure, economic problems and traffic accidents; (2) use of steroid medication; (3) physical illness (e.g. encephalitis, brain injury, epilepsy and endocrine diseases); (4) other axis I psychiatric disorders (e.g. dementia, generalized anxiety disorder, schizophrenia, obsessive–compulsive disorder, bipolar disorder, and alcohol or substance abuse; and (5) pregnant or breast feeding.

We also recruited 36 pairwise and age-matched healthy controls who met the following criteria: (1) normal social function; (2) no psychiatric disease; and (3) no physical illness. Any healthy controls or patients with dyed hair were excluded, as bleaching and dyeing can affect HCC. All participants provided written informed consent before participating in the research, and the research was approved by the Institutional Ethics Committee of Sichuan University.
Because some individuals’ hair was too short to provide an adequate sample, we did not analyse data from all patients taking antidepressants. The patients took medication for 4 weeks. During the treatment period, 15 patients were temporarily treated for sleep disorders with benzodiazepines or sleep medications, and were not treated with other types of antipsychotic drugs. The control group received no intervention.

**Hair collection and cortisol analysis**

Hair samples were collected as previously described. Hair strands were cut using scissors from a posterior vertex position as proximal as possible to the scalp, wrapped in aluminium foil and stored in separate airtight plastic bags at room temperature until extraction. For controls, a 1-cm segment close to the scalp was cut. For patients taking antidepressants, a 1-cm hair segment close to the scalp was cut and labelled as pre-treatment; after the treatment period, another 1-cm hair segment close to the scalp from the same region as the first cut was collected and labelled as post-treatment.

After sample collection, the samples were centralized to determine HCC and to ensure the consistency of the processing procedure. Hair cortisol levels were determined using an electrochemiluminescence immune assay with Elecsys analysers (Roche, Basel, Switzerland).

The hair cortisol extraction and analysis methods have been previously described. All samples were determined in duplicate, and the mean values of the two tests (pre-treatment and post-treatment) were analysed. The intra-assay and inter-assay coefficients of variation were below 8%.

**Assessment of clinical symptoms**

Patient depression severity (pre-treatment and post-treatment) was determined by trained psychiatrists using the 17-item Hamilton Depression Rating Scale (HAMD).

**Statistical analysis**

We conducted a test of normality of HCC variances using the K-S method and applied log transformations to ensure that the data conformed to the normal distribution. One-way analysis of variance (ANOVA) and $\chi^2$ tests were conducted to compare the characteristics of the three groups. We performed t-tests for independent samples to compare pre-treatment and post-treatment patient HAMD scores. One-way ANOVA was conducted to compare HCC means among patients at pre-treatment, patients at post-treatment, and healthy controls. If the ANOVA P-value was <0.05, subsequent posthoc least significant difference tests were performed. Pearson correlations were calculated to explore the relationship between HAMD scores and HCC of patients at pre-treatment and at post-treatment. For all analyses, a P-value <0.05 was considered statistically significant.

**Results**

**Sociodemographic characteristics**

Forty-two patients and 36 healthy individuals completed the baseline HCC assessment. Of the 42 patients, 26 completed the post-treatment HCC assessment. Data were analysed from 26 patients: 10 patients taking escitalopram (mean $= 16$ mg/d); 7 patients taking paroxetine (mean $= 31$ mg/d); 3 patients taking sertraline (mean $= 92$ mg/d); 1 patient taking citalopram (mean $= 10$ mg/d); 3 patients taking venlafaxine (mean $= 92$ mg/d); 1 patient taking duloxetine (mean $= 40$ mg/d) and 1 patient taking mirtazapine (mean $= 15$ mg/d). There were no significant differences in age, sex or education years among patients.
at pre-treatment, patients at post-treatment, and healthy controls, but HAMD scores differed significantly between patients at pre-treatment and those at post-treatment (Table 1).

**Comparison of cortisol concentration**

There was a significant difference in HCC among the three groups ($F = 10.36, P < 0.001, \eta^2 = 0.21$). We then compared the HCC of the 36 healthy individuals and the 42 patients at pre-treatment, of the 36 healthy individuals and the 26 patients at post-treatment, and of the 42 patients at pre-treatment and the 26 patients at post-treatment. The post-treatment patient HCC (mean ± standard deviation: $34.40 ± 32.57$ pmol/mg) was significantly higher than the pre-treatment patient HCC ($17.42 ± 12.40$ pmol/mg, $P = 0.036$) and the healthy control HCC ($10.22 ± 7.99$ pmol/mg, $P < 0.001$) (Table 2).

**Correlation between HCC and HAMD scores**

No significant correlation was found between HCC and HAMD scores at pre-treatment ($r = 0.022$) or post-treatment ($r = 0.136$).

**Discussion**

We found a significantly higher HCC for patients with depression at pre-treatment than for healthy controls. This result is con-

---

### Table 1. Comparison of sociodemographic characteristics between patients with depression and healthy controls.

| Sociodemographic characteristics | Patients | Controls | F/\(\chi^2/t\) | P |
|----------------------------------|----------|----------|---------------|---|
|                                  | Pre-treatment (n = 42) | Post-treatment (n = 26) | Controls (n = 36) |  |
| Age                              | 46.05 ± 10.16 | 46.92 ± 7.53 | 43.22 ± 11.04 | 1.26 | 0.29 |
| Sex: Males (Females)             | 6 (36) | 3 (23) | 12 (24) | 5.76 | 0.06 |
| Education years                  | 8.05 ± 4.48 | 6.96 ± 4.89 | 8.67 ± 4.51 | 1.05 | 0.36 |
| Psychoactive medication          | 40 | 26 | | |
| SSRI                             | 35 | 24 | | |
| Dual AD                          | 4 | 2 | | |
| Other AD                         | 1 | 0 | | |
| Benzodiazepines/sleep medicines  | 15 | 9 | | |
| HAMD-17                          | 23.86 ± 5.42 | 6.23 ± 4.90 | | 14.14 | <0.01 |

SSRI: selective serotonin reuptake inhibitor; AD: antidepressant; Dual AD: venlafaxine or duloxetine; HAMD-17: Hamilton Depression Rating Scale.

### Table 2. Analysis of variance results comparing hair cortisol concentrations.

| | ANOVA | Posthoc test (P-values) |
|---|---|---|---|---|---|---|---|
| | | Pre-treatment vs. Controls | Post-treatment vs. Controls | Pre-treatment vs. Post-treatment |
| | F | P | | | | |
| Pre-treatment | Post-treatment | Controls | 10.36 | <0.001 | 0.007 | <0.001 | 0.036 |
| 17.42 ± 12.40 | 34.40 ± 32.57 | 10.2 ± 7.99 | |

ANOVA: analysis of variance.
sistent with previous findings that HCC is higher in patients with depression than in comparable controls.\textsuperscript{6} Our results also extend previous work by Wei et al., who examined female patients with depression.\textsuperscript{6,31}

After 4 weeks of antidepressant treatment, patient HCC was significantly higher than patient pre-treatment HCC and control HCC. HCC reflects the average level of cortisol over a period of time, which may differ from cortisol levels in serum or urine samples.\textsuperscript{31} That is, the cortisol concentration in 1 cm of hair represents the average level over 1 month. We found that if depression was not well controlled while the patient was taking antidepressant medication, the cortisol concentration continued to increase, and then decreased over time. However, as the margin of decrease was small, the average cortisol concentration was still higher than that before treatment. This assumption requires further verification. Dettenborn et al. found that medicated patients with depression had elevated HCC compared with controls, and medicated patients had higher HCC in the first hair segment (the scalp near the posterior vertex position) (mean ± standard deviation: 26.7 ± 20.8 pg/mg) than in the second (21.9 ± 23.7 pg/mg), which suggests that cortisol concentrations did not return to normal 6 months after antidepressant treatment.\textsuperscript{6} We need to extend the follow-up time to further observe changes in hair cortisol. Dettenborn et al. also suggested that studies of antidepressant effects on the HPA system should examine both the clinical response to treatment and the type of HPA axis measure.\textsuperscript{36–38} The long-term effects of antidepressant drugs on the HPA axis require further investigation before firm conclusions can be drawn.

Previous research suggests that high serum cortisol concentrations in depressed patients may also be influenced by the potentially stressful effects of hospitalization and testing, at least for the most vulnerable patients.\textsuperscript{39} Interaction with physicians, the hospital setting (and separation from their families), different diet and concerns about treatment options may affect changes in hair cortisol levels in depressed patients. One study showed that unsatisfactory dyadic relationships may influence normal HPA axis function because of external stress.\textsuperscript{40} Persons who experience poor dyadic relationships also show elevated HPA axis responses to stress.\textsuperscript{41} Conversely, the use of couple-coping strategies is associated with overall marital satisfaction and also with reduced HPA axis responses to laboratory stressors.\textsuperscript{42,43} When a partner becomes a patient, this may affect the relationship and cause changes in cortisol concentrations.

One study found that hair cortisol measures are reliable, valid and convenient measures of cortisol in patients and healthy individuals, suggesting that hair cortisol may be a potential biomarker for prolonged cortisol exposure and thus useful in the development and implementation of more effective depression treatments.\textsuperscript{25,39,44} However, it remains unclear whether hair cortisol levels reflect adrenal cortex secretion or intrafollicular production, or both. Human hair follicles possess their own HPA axis, commonly referred to as the ‘peripheral’ HPA axis.\textsuperscript{45–49} Hair cortisol is likely to reflect the activity of hair follicle HPA axis activity and therefore represents a ‘peripheral’ rather than a ‘central’ response to stress. Therefore, we cannot rule out the possibility that the elevated HCC found for patients with depression in this study reflects only follicle-based production. However, hair cortisol levels in rhesus monkeys and healthy humans correlate highly with salivary cortisol samples.\textsuperscript{50,51} Sauve has reported that HCC correlates strongly with 24-hour urinary cortisol.\textsuperscript{33} D’Anna-Hernandez and van Holland found the same association in pregnant women and in construction
workers, respectively. All these studies support the idea that HCC reflects stem cell activity in the adrenal glands. However, these studies provide only indirect evidence for adrenal sources of hair cortisol. Therefore, further research is needed to confirm the sources of HCC.

We found no significant correlation between HAMD scores and HCC in patients with depression either at pre-treatment or post-treatment, a finding inconsistent with previous studies using non-hair samples. Two factors may explain this inconsistency. First, the retrospective nature of hair analysis allows the measurement of average cortisol levels over a specific period of time, which may differ from cortisol concentrations in serum or urine samples. Second, the effects of antidepressants should be considered in interpreting results. This study had several limitations. First, the sample was small, which may reduce the reliability of the results. Second, we found a significantly high HCC after 4 weeks antidepressant treatment, which may indicate that the antidepressant treatment did not result in optimum depression control within the 4 weeks. In fact, it can take 2 to 4 weeks (and sometimes 6 weeks) for antidepressants to take effect. Third, antidepressant drugs should be selected based on their different specific mechanisms of action to enhance the clarity of results.

In summary, we found that the HCC of patients with depression increased significantly at post-treatment. HCC analysis could be used to monitor the dynamics of the effects of antidepressants on the HPA axis.

Acknowledgments
The authors thank Professor Dongtao Lin of Sichuan University for copyediting this manuscript.

Declaration of conflicting interest
The authors declare that there is no conflict of interest.

Funding
This research was partly funded by a National Science and Technology Support Plan (2015BA113B02) and State 863 Projects (2015AA020513).

ORCID iD
Xiaohong Ma https://orcid.org/0000-0002-1213-2268

References
1. Seol GH, Shim HS, Kim PJ, et al. Antidepressant-like effect of Salvia sclarea is explained by modulation of dopamine activities in rats. *J Ethnopharmacol* 2010; 130: 187–190.
2. Knorr U, Vinberg M, Kessing LV, et al. Salivary cortisol in depressed patients versus control persons: a systematic review and meta-analysis. *Psychoneuroendocrinology* 2010; 35: 1275–1286.
3. Stetler C and Miller GE. Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research. *Psychosom Med* 2011; 73: 114–126.
4. Weinstein AA, Deuster PA, Francis JL, et al. Neurohormonal and inflammatory hyper-responsiveness to acute mental stress in depression. *Biol Psychol* 2010; 84: 228–234.
5. Meyer JS and Novak MA. Minireview: hair cortisol: a novel biomarker of hypothalamic-pituitary-adrenocortical activity. *Endocrinology* 2012; 153: 4120–4127.
6. Dettenborn L, Muhtz C, Skoluda N, et al. Introducing a novel method to assess cumulative steroid concentrations: increased hair cortisol concentrations over 6 months in medicated patients with depression. *Stress* 2012; 15: 348–353.
7. Brouwer JP, Appelhof BC, Hoogendijk WJ, et al. Thyroid and adrenal axis in major depression: a controlled study in outpatients. *Eur J Endocrinol* 2005; 152: 185–191.
8. Goldberg JF, Harrow M and Whiteside JE. Risk for bipolar illness in patients initially hospitalized for unipolar depression. *Am J Psychiatry* 2001; 158: 1265–1270.

9. Oldehinkel AJ and Bouma EM. Sensitivity to the depressogenic effect of stress and HPA-axis reactivity in adolescence: a review of gender differences. *Neurosci Biobehav Rev* 2011; 35: 1757–1770.

10. Mason BL and Pariante CM. The effects of antidepressants on the hypothalamic-pituitary-adrenal axis. *Drug News Perspect* 2006; 19: 603–608.

11. Piwowarska J, Wrzosek M, Radziwon-Zaleska M, et al. Serum cortisol concentration in patients with major depression after treatment with clomipramine. *Pharmacol Rep* 2009; 61: 604–611.

12. Grass J, Kirschbaum C, Miller R, et al. Sweat-inducing physiological challenges do not result in acute changes in hair cortisol concentrations. *Psychoneuroendocrinology* 2015; 53: 108–116.

13. Pruessner JC, Kirschbaum C, Meinschmid G, et al. Two formulas for computation of the area under the curve represent measures of total hormone concentration versus time-dependent change. *Psychoneuroendocrinology* 2003; 28: 916–931.

14. Gibson EL, Checkley S, Papadopoulos A, et al. Increased salivary cortisol reliably induced by a protein-rich midday meal. *Psychosom Med* 1999; 61: 214–224.

15. Galbo H. Endocrinology and metabolism in exercise. *Curr Prob Clin Biochem* 1982; 11: 26–44.

16. Gow R, Thomson S, Rieder M, et al. An assessment of cortisol analysis in hair and its clinical applications. *Forensic Sci Int* 2010; 196: 32–37.

17. Thomson S, Koren G, Fraser LA, et al. Hair analysis provides a historical record of cortisol levels in Cushing’s syndrome. *Exp Clin Endocrinol Diabetes* 2010; 118: 32–37.

18. Van Uum SH, Saue B, Fraser LA, et al. Elevated content of cortisol in hair of patients with severe chronic pain: a novel biomarker for stress. *Stress* 2008; 11: 483–488.

19. Manenschijn L, Koper JW, Lamberts SW, et al. Evaluation of a method to measure long term cortisol levels. *Steroids* 2011; 76: 1032–1036.

20. Raul JS, Cirimele V, Ludes B, et al. Detection of physiological concentrations of cortisol and cortisone in human hair. *Clin Biochem* 2004; 37: 1105–1111.

21. Sharpley CF, Kauter KG and McFarlane JR. An investigation of hair cortisol concentration across body sites and within hair shaft. *Clin Med Insights Endocrinol Diabetes* 2010; 3: 17–23.

22. Dettenborn L, Tietze A, Kirschbaum C, et al. The assessment of cortisol in human hair: associations with sociodemographic variables and potential confounders. *Stress* 2012; 15: 578–588.

23. Kirschbaum C, Tietze A, Skoluda N, et al. Hair as a retrospective calendar of cortisol production-increased cortisol incorporation into hair in the third trimester of pregnancy. *Psychoneuroendocrinology* 2009; 34: 32–37.

24. Hinkelmann K, Muhtz C, Dettenborn L, et al. Association between childhood trauma and low hair cortisol in depressed patients and healthy control subjects. *Biol Psychiatry* 2013; 74: e15–e17.

25. Herane Vives A, De Angel V, Papadopoulos A, et al. The relationship between cortisol, stress and psychiatric illness: new insights using hair analysis. *J Psychiatr Res* 2015; 70: 38–49.

26. Schule C. Neuroendocrinological mechanisms of actions of antidepressant drugs. *J Neuroendocrinol* 2007; 19: 213–226.

27. Laakmann G, Hennig J, Baghai T, et al. Influence of mirtazapine on salivary cortisol in depressed patients. *Neuropsychobiology* 2003; 47: 31–36.

28. Laakmann G, Hennig J, Baghai T, et al. Mirtazapine acutely inhibits salivary cortisol concentrations in depressed patients. *Ann N Y Acad Sci* 2004; 1032: 279–282.

29. Sarubin N, Nothdurfter C, Schmotz C, et al. Impact on cortisol and antidepressant efficacy of quetiapine and escitalopram in depression. *Psychoneuroendocrinology* 2014; 39: 141–151.

30. Bschor T, Ising M, Erbe S, et al. Impact of citalopram on the HPA system. A study of the combined DEX/CRH test in 30 unipolar
depresseed patients. *J Psychiatr Res* 2012; 46: 111–117.

31. Wei J, Sun G, Zhao L, et al. Analysis of hair cortisol level in first-episodic and recurrent female patients with depression compared to healthy controls. *J Affect Disord* 2015; 175: 299–302.

32. Yang X, Sun G, Wei J, et al. Comparison of hair thyroid hormones between first-episode and recurrent patients with depression in female Chinese. *Asia Pac Psychiatry* 2016; 8: 302–305.

33. Sauve B, Koren G, Walsh G, et al. Measurement of cortisol in human hair as a biomarker of systemic exposure. *Clin Invest Med* 2007; 30: E183–E191.

34. Luo H, Hu X, Liu X, et al. Hair cortisol level as a biomarker for altered hypothalamic-pituitary-adrenal activity in female adolescents with posttraumatic stress disorder after the 2008 Wenchuan earthquake. *Biol Psychiatry* 2012; 72: 65–69.

35. Montgomery SA and Asberg M. A new depression scale designed to be sensitive to change. *Br J Psychiatry* 1979; 134: 382–389.

36. Kauffman RP, Castracane VD, White DL, et al. Impact of the selective serotonin reuptake inhibitor citalopram on insulin sensitivity, leptin and basal cortisol secretion in depressed and non-depressed euglycemic women of reproductive age. *Gynecol Endocrinol* 2005; 21: 129–137.

37. Schule C, Baghai TC, Eser D, et al. Time course of hypothalamic-pituitary-adrenocortical axis activity during treatment with reboxetine and mirtazapine in depressed patients. *Psychopharmacology (Berl)* 2006; 186: 601–611.

38. Scharnholz B, Weber-Hamann B, Lederbogen F, et al. Antidepressant treatment with mirtazapine, but not venlafaxine, lowers cortisol concentrations in saliva: a randomised open trial. *Psychiatry Res* 2010; 177: 109–113.

39. Pochigaeva K, Druzhkova T, Yakovlev A, et al. Hair cortisol as a marker of hypothalamic-pituitary-adrenal Axis activity in female patients with major depressive disorder. *Metab Brain Dis* 2017; 32: 577–583.

40. Luginbuehl T and Schoebl D. Emotion dynamics and responsiveness in intimate relationships. *Emotion* 2019. doi: 10.1037/emo0000540. [Epub ahead of print]

41. Stanton SC and Campbell L. Psychological and physiological predictors of health in romantic relationships: an attachment perspective. *J Pers* 2014; 82: 528–538.

42. Sharpley CF, Bitsika V, McMillan ME, et al. Dyadic coping and the cortisol:CRP ratio: how marital stress influences physiological state. *Physiol Behav* 2019; 211: 112669.

43. Meuwly N, Bodenmann G, Germann J, et al. Dyadic coping, insecure attachment, and cortisol stress recovery following experimentally induced stress. *J Fam Psychol* 2012; 26: 937–947.

44. Staufenbiel SM, Penninx BW, Spijker AT, et al. Hair cortisol, stress exposure, and mental health in humans: a systematic review. *Psychoneuroendocrinology* 2013; 38: 1220–1235.

45. Ito N, Ito T, Kromminga A, et al. Human hair follicles display a functional equivalent of the hypothalamic-pituitary-adrenal axis and synthesize cortisol. *FASEB J* 2005; 19: 1332–1334.

46. Slominski A, Wortsman J, Luger T, et al. Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress. *Physiol Rev* 2000; 80: 979–1020.

47. Slominski A and Mihm MC. Potential mechanism of skin response to stress. *Int J Dermatol* 1996; 35: 849–851.

48. Slominski A, Wortsman J, Tuckey RC, et al. Differential expression of HPA axis homolog in the skin. *Mol Cell Endocrinol* 2007; 265–266: 143–149.

49. Slominski A and Wortsman J. Neuroendocrinology of the skin. *Endocr Rev* 2000; 21: 457–487.

50. Davenport MD, Tiefenbacher S, Lutz CK, et al. Analysis of endogenous cortisol concentrations in the hair of rhesus macaques. *Gen Comp Endocrinol* 2006; 147: 255–261.

51. Xie Q, Gao W, Li J, et al. Correlation of cortisol in 1-cm hair segment with salivary cortisol in human: hair cortisol as an endogenous biomarker. *Clin Chem Lab Med* 2011; 49: 2013–2019.
52. D’Anna-Hernandez KL, Ross RG, Natvig CL, et al. Hair cortisol levels as a retrospective marker of hypothalamic-pituitary axis activity throughout pregnancy: comparison to salivary cortisol. *Physiol Behav* 2011; 104: 348–353.

53. van Holland BJ, Frings-Dresen MH, Sluiter JK. Measuring short-term and long-term physiological stress effects by cortisol reactivity in saliva and hair. *Int Arch Occup Environ Health* 2012; 85: 849–852.

54. Grant MM, Friedman ES, Haskett RF, et al. Urinary free cortisol levels among depressed men and women: differential relationships to age and symptom severity? *Arch Womens Ment Health* 2007; 10: 73–78.

55. Li H, Gao Z, Wu Q, et al. Relationship of hypothalamus-pituitary-adrenal (HPA) axis function and suicidal behavior in patients with depression. *Shanghai Arch Psychiatry* 2013; 25: 32–39.

56. Quitkin FM, Rabkin JG, Ross D, et al. Duration of antidepressant drug treatment. What is an adequate trial? *Arch Gen Psychiatry* 1984; 41: 238–245.